纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | MYH6 |
Uniprot No | P13533 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 160-816aa |
氨基酸序列 | NAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFASIAAIGDRGKKDNANANKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERNYHIFYQILSNKKPELLDMLLVTNNPYDYAFVSQGEVSVASIDDSEELMATDSAFDVLGFTSEEKAGVYKLTGAIMHYGNMKFKQKQREEQAEPDGTEDADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQSVQQVYYSIGALAKAVYEKMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLYDNHLGKSNNFQKPRNIKGKQEAHFSLIHYAGTVDYNILGWLEKNKDPLNETVVALYQKSSLKLMATLFSSYATADTGDSGKSKGGKKKGSSFQTVSALHRENLNKLMTNLRTTHPHFVRCIIPNERKAPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPVAIPEGQFIDSRKGTEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRMQAQARGQLMRIEFKKIVERRDALLVI |
预测分子量 | 80.8 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MYH6重组蛋白的三篇参考文献的简要概括(注:以下内容为示例性虚构,实际文献需通过学术数据库检索确认):
---
1. **文献名称**: "Recombinant Expression and Functional Analysis of Human MYH6 in Insect Cells"
**作者**: Smith J, et al.
**摘要**: 本研究利用杆状病毒-昆虫细胞系统成功表达了人源MYH6重组蛋白,并验证其ATP酶活性及与肌动蛋白的结合能力,为研究心肌收缩机制提供功能性工具。
2. **文献名称**: "Structural Insights into MYH6 Mutants via Recombinant Protein Crystallography"
**作者**: Lee S, et al.
**摘要**: 通过大肠杆菌表达系统获得MYH6及其致病突变体的重组蛋白,结合X射线晶体学揭示了突变导致的结构异常,阐明其与先天性心脏病的分子关联。
3. **文献名称**: "High-Yield Purification of Recombinant MYH6 for Therapeutic Screening"
**作者**: Garcia R, et al.
**摘要**: 开发了一种高效哺乳动物细胞表达体系及层析纯化策略,获得高纯度MYH6蛋白,应用于心肌病相关药物的高通量筛选平台构建。
---
如需真实文献,建议在PubMed或Web of Science中检索关键词“MYH6 recombinant protein”或“MYH6 expression purification”获取最新研究。
MYH6 recombinant protein is derived from the MYH6 gene, which encodes the alpha-myosin heavy chain (α-MHC), a critical component of cardiac muscle contraction. As a member of the myosin superfamily, MYH6 is predominantly expressed in the atrial and embryonic ventricular myocardium, playing a vital role in heart development and function. This protein forms the motor domain of myosin, enabling ATP-dependent interaction with actin filaments to generate mechanical force during systole. Mutations in MYH6 are linked to congenital heart defects, cardiomyopathies, and arrhythmias, making it a focus of cardiovascular research.
Recombinant MYH6 is typically produced using expression systems like Escherichia coli or mammalian cells, ensuring proper folding and post-translational modifications. Its production enables in vitro studies to dissect molecular mechanisms of cardiac diseases, screen therapeutic compounds, and model pathogenic mutations. Researchers utilize this protein to investigate how specific variants impair contractility, alter calcium sensitivity, or disrupt sarcomere assembly—key factors in conditions like hypertrophic cardiomyopathy (HCM) and atrial septal defects.
In diagnostics, recombinant MYH6 serves as an antigen for antibody development, aiding in the detection of autoimmune responses in myocarditis. It also supports structural biology studies, facilitating crystallography or cryo-EM analyses to map mutation sites and design targeted drugs. Recent advances in gene therapy have spurred interest in MYH6 as a potential therapeutic target, particularly for restoring contractile function in failing hearts.
Quality-controlled batches are essential for experimental reproducibility, often verified via SDS-PAGE, western blot, and functional assays. By bridging basic science and clinical applications, MYH6 recombinant protein remains a cornerstone for understanding cardiac pathophysiology and developing precision medicine approaches.
×